Journal
PHARMACOLOGICAL RESEARCH
Volume 102, Issue -, Pages 245-253Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2015.10.014
Keywords
11 beta-hydroxysteroid dehydrogenase type 1; Tanshinone IIA; High-throughput screening; Adipogenesis; Diabetes; Metabolic syndrome
Categories
Funding
- R&D Convergence Program of MSIP (Ministry of Science, ICT and Future Planning)
- ISTK (Korea Research Council for Industrial Science and Technology) of the Republic of Korea [B551179-13-02-09]
- Korea Research Institute of Chemical Technology
- Ministry of Knowledge Economy, Republic of Korea
Ask authors/readers for more resources
Selective inhibitors of 11 p-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) have considerable potential as a treatment for metabolic syndrome including type 2 diabetes mellitus and obesity. To identify 11 beta-HSD1 inhibitors, we conducted high-throughput screening (HTS) of active natural product extracts from the Korea Chemical Bank, including Tanshinone I, Tanshinone IIA, and flavanone derivatives, and 2- and 3-phenyl-4H-chromen-4-one. Then Tanshinone IIA and its derivatives were targeted for the development of a lead compound according to the HTS results. However, the mechanism for anti-adipogenic effect through 11 beta-HSD1 enzyme inhibition by Tanshinone IIA is not clear. Tanshinone IIA (2a) concentrationdependently inhibited 11 beta-HSD1 activity in human and mouse 11 beta-HSD1 overexpressed cells and 3T3-L1 adipocytes. Tanshinone IIA (2a) also inhibited 11 beta-HSD1 enzyme activities in murine liver and fats. Furthermore, Tanshinone IIA (2a)-suppressed adipocyte differentiation of cortisone-induced adipogenesis in 3T3-L1 cells was associated with the suppression of the cortisone-induced adipogenesis-specific markers mRNA and protein expression. In 3T3-L1 preadipocytes, Tanshinone IIA (2a)-inhibited cortisone induced reactive oxygen species formation in a concentration-dependent manner. Thus, these results support the therapeutic potential of Tanshinone IIA (2a) as a 11 beta-HSD1 inhibitor in metabolic syndrome patients. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available